HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meis, P. J. Search for Related Content PubMed PubMed Citation Articles by Meis, P. J. Related Collections Epidemiology/public health General obstetrics

17 Hydroxyprogesterone for the Prevention of Preterm Delivery

From the Department of Obstetrics and Gynecology, Maternal–Fetal Medicine, Winston-Salem, North Carolina.

We have invited select authorities to present background information on challenging clinical problems and practical information on diagnosis and treatment for use by practitioners.

The recent publication of 2 large randomized trials of 17 alpha hydroxyprogesterone caproate (17P) and progesterone suppositories, respectively, for the prevention of premature labor have renewed interest in the use of progesterone to prevent preterm birth. The results of these trials have reinforced the positive results of earlier smaller trials of 17P to prevent preterm delivery. A large body of evidence attests to the lack of teratogenic effects of 17P in pregnancy. Although progesterone is known to have many actions beneficial to the maintenance of pregnancy, the exact mode of action of 17P therapy in preventing preterm labor and delivery is not known. Current evidence supports the use of 17P treatment, begun early in the second trimester of gestation and continued weekly until 36 weeks, for women with a history of a previous spontaneous preterm delivery. At present no evidence exists for the use of 17P to prevent preterm delivery in women with multiple gestation, a short uterine cervix, or other high-risk conditions. The use of 17P or other progestins should not be encouraged for these indications outside of randomized trials. At present no evidence exists for the efficacy of any oral progesterone compound in preventing preterm labor. Four trials reporting the use of a progestational drug in patients with symptoms of preterm labor found no efficacy in prolonging pregnancy, and the use of 17P or other progestational drugs as tocolytic therapy should not be encouraged.

This article has been cited by other articles:

				A. Rebarber, N. B. Istwan, K. Russo-Stieglitz, J. Cleary-Goldman, D. J. Rhea, G. J. Stanziano, and D. H. Saltzman Increased Incidence of Gestational Diabetes in Women Receiving Prophylactic 17{alpha}-Hydroxyprogesterone Caproate for Prevention of Recurrent Preterm Delivery Diabetes Care, September 1, 2007; 30(9): 2277 - 2280. [Abstract] [Full Text] [PDF]

				S. P. Ng, B. G. Steinetz, S. G. Lasano, and J. T. Zelikoff Hormonal Changes Accompanying Cigarette Smoke-Induced Preterm Births in a Mouse Model Experimental Biology and Medicine, September 1, 2006; 231(8): 1403 - 1409. [Abstract] [Full Text] [PDF]

				N. R. Chapman, M. M. Kennelly, K. A. Harper, G. N. Europe-Finner, and S. C. Robson Examining the spatio-temporal expression of mRNA encoding the membrane-bound progesterone receptor-alpha isoform in human cervix and myometrium during pregnancy and labour Mol. Hum. Reprod., January 1, 2006; 12(1): 19 - 24. [Abstract] [Full Text] [PDF]